Annual Cash & Cash Equivalents
$51.35 M
-$35.17 M-40.65%
December 31, 2023
Summary
- As of February 20, 2025, ADMA annual cash & cash equivalents is $51.35 million, with the most recent change of -$35.17 million (-40.65%) on December 31, 2023.
- During the last 3 years, ADMA annual cash & cash equivalents has fallen by -$4.57 million (-8.17%).
- ADMA annual cash & cash equivalents is now -40.65% below its all-time high of $86.52 million, reached on December 31, 2022.
Performance
ADMA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$86.71 M
-$1.54 M-1.74%
September 30, 2024
Summary
- As of February 20, 2025, ADMA quarterly cash and cash equivalents is $86.71 million, with the most recent change of -$1.54 million (-1.74%) on September 30, 2024.
- Over the past year, ADMA quarterly cash and cash equivalents has stayed the same.
- ADMA quarterly cash and cash equivalents is now -14.35% below its all-time high of $101.24 million, reached on March 31, 2020.
Performance
ADMA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ADMA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -40.6% | 0.0% |
| 3 y3 years | -8.2% | +0.2% |
| 5 y5 years | +125.7% | +0.2% |
ADMA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.6% | +0.5% | -1.7% | +148.4% |
| 5 y | 5-year | -40.6% | +92.0% | -14.3% | +224.1% |
| alltime | all time | -40.6% | >+9999.0% | -14.3% | >+9999.0% |
ADMA Biologics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $86.71 M(-1.7%) |
| Jun 2024 | - | $88.24 M(+94.7%) |
| Mar 2024 | - | $45.33 M(-11.7%) |
| Dec 2023 | $51.35 M(-40.6%) | $51.35 M(-30.8%) |
| Sep 2023 | - | $74.16 M(+18.6%) |
| Jun 2023 | - | $62.51 M(-9.7%) |
| Mar 2023 | - | $69.20 M(-20.0%) |
| Dec 2022 | $86.52 M(+69.4%) | $86.52 M(+147.9%) |
| Sep 2022 | - | $34.91 M(-33.4%) |
| Jun 2022 | - | $52.42 M(-24.6%) |
| Mar 2022 | - | $69.50 M(+36.0%) |
| Dec 2021 | $51.09 M(-8.6%) | $51.09 M(+48.5%) |
| Sep 2021 | - | $34.41 M(-18.9%) |
| Jun 2021 | - | $42.41 M(-31.6%) |
| Mar 2021 | - | $61.97 M(+10.8%) |
| Dec 2020 | $55.92 M(+109.0%) | $55.92 M(-6.3%) |
| Sep 2020 | - | $59.67 M(-21.3%) |
| Jun 2020 | - | $75.78 M(-25.1%) |
| Mar 2020 | - | $101.24 M(+278.4%) |
| Dec 2019 | $26.75 M(+17.6%) | $26.75 M(-44.3%) |
| Sep 2019 | - | $48.01 M(-34.8%) |
| Jun 2019 | - | $73.62 M(+345.2%) |
| Mar 2019 | - | $16.53 M(-27.3%) |
| Dec 2018 | $22.75 M(-47.2%) | $22.75 M(-46.3%) |
| Sep 2018 | - | $42.37 M(-23.2%) |
| Jun 2018 | - | $55.15 M(+111.2%) |
| Mar 2018 | - | $26.12 M(-39.4%) |
| Dec 2017 | $43.11 M | $43.11 M(+216.9%) |
| Sep 2017 | - | $13.60 M(-46.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $25.57 M(+199.4%) |
| Mar 2017 | - | $8.54 M(-13.8%) |
| Dec 2016 | $9.91 M(-5.0%) | $9.91 M(+25.4%) |
| Sep 2016 | - | $7.91 M(-37.0%) |
| Jun 2016 | - | $12.55 M(+40.6%) |
| Mar 2016 | - | $8.93 M(-14.5%) |
| Dec 2015 | $10.44 M(-39.3%) | $10.44 M(+13.8%) |
| Sep 2015 | - | $9.18 M(+17.3%) |
| Jun 2015 | - | $7.82 M(-52.8%) |
| Mar 2015 | - | $16.56 M(-3.7%) |
| Dec 2014 | $17.20 M(-34.2%) | $17.20 M(+23.3%) |
| Sep 2014 | - | $13.95 M(-21.9%) |
| Jun 2014 | - | $17.87 M(-32.6%) |
| Mar 2014 | - | $26.52 M(+1.4%) |
| Dec 2013 | $26.15 M(+108.6%) | $26.15 M(+386.1%) |
| Sep 2013 | - | $5.38 M(-29.7%) |
| Jun 2013 | - | $7.65 M(-25.8%) |
| Mar 2013 | - | $10.32 M(-17.7%) |
| Dec 2012 | $12.54 M(>+9900.0%) | $12.54 M(+16.9%) |
| Sep 2012 | - | $10.72 M(-16.8%) |
| Jun 2012 | - | $12.89 M(-9.5%) |
| Mar 2012 | - | $14.24 M(>+9900.0%) |
| Dec 2011 | - | $8100.00(+37.3%) |
| Sep 2011 | - | $5900.00(-30.6%) |
| Jun 2011 | $8500.00(-29.2%) | $8500.00(-47.5%) |
| Mar 2011 | - | $16.20 K(+422.6%) |
| Dec 2010 | - | $3100.00(-74.2%) |
| Jun 2010 | - | $12.00 K |
| Jun 2010 | $12.00 K | - |
FAQ
- What is ADMA Biologics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ADMA Biologics?
- What is ADMA Biologics annual cash & cash equivalents year-on-year change?
- What is ADMA Biologics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ADMA Biologics?
- What is ADMA Biologics quarterly cash and cash equivalents year-on-year change?
What is ADMA Biologics annual cash & cash equivalents?
The current annual cash & cash equivalents of ADMA is $51.35 M
What is the all time high annual cash & cash equivalents for ADMA Biologics?
ADMA Biologics all-time high annual cash & cash equivalents is $86.52 M
What is ADMA Biologics annual cash & cash equivalents year-on-year change?
Over the past year, ADMA annual cash & cash equivalents has changed by -$35.17 M (-40.65%)
What is ADMA Biologics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ADMA is $86.71 M
What is the all time high quarterly cash and cash equivalents for ADMA Biologics?
ADMA Biologics all-time high quarterly cash and cash equivalents is $101.24 M
What is ADMA Biologics quarterly cash and cash equivalents year-on-year change?
Over the past year, ADMA quarterly cash and cash equivalents has changed by $0.00 (0.00%)